ArticleAnnals of nuclear medicine2026
Association of SUVmax and never-smoker/never- or minimally-drinker history with PD-L1 expression in resected oral squamous cell carcinoma: a nodal-status-stratified analysis.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundProgrammed death-ligand 1 (PD-L1) is a critical biomarker for immunotherapy selection in oral squamous cell carcinoma (OSCC). However, the relationships between PD-L1 expression and non-invasive indicators, such as metabolic parameters derived from
methodsThis retrospective study included 147 patients with resected OSCC who underwent preoperative PET/CT. Factors associated with high PD-L1 expression (combined positive score [CPS] ≥ 20) were assessed using logistic regression in the overall cohort and with subgroup analyses stratified by nodal status and formal interaction testing.
resultsIn the overall cohort, maximum standardized uptake value (SUVmax) (odds ratio [OR] per unit increase = 1.067; 95% confidence interval [CI]: 1.013-1.123; P = 0.014) and gender (OR = 2.254; 95% CI: 1.029-4.936; P = 0.042) were independently associated with high PD-L1 expression. After stratification by nodal status, no clinicopathological or metabolic variable was significantly associated with PD-L1 expression in pN0 patients. In contrast, among pN+ patients, SUVmax (OR per unit increase = 1.113; 95% CI: 1.015-1.222; P = 0.024) and NSND (OR = 4.127; 95% CI: 1.362-12.501; P = 0.012) emerged as independent predictors. The NSND × pN interaction was significant (P = 0.004), whereas the SUVmax × pN interaction was not (P = 0.225).
conclusionsSUVmax may serve as a candidate non-invasive indicator, whereas the association between NSND and high PD-L1 expression was modified by nodal status, with a significant effect in node-positive patients. These findings are hypothesis-generating and require external validation.
Indexed as
Identifiers
42862275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.